United Therapeutics (UTHR) Tops Q2 EPS by 24c
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $494.63 -0.53%
Revenue Growth %: -1.2%
Financial Fact:
Income tax expense: -77.3M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -1.2%
Financial Fact:
Income tax expense: -77.3M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $2.55, $0.24 better than the analyst estimate of $2.31. Revenue for the quarter came in at $347.2 million versus the consensus estimate of $360.41 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Lumentum shares rise on analyst upgrades, AI demand outlook
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
